Local ablative treatment and continuation of systemic therapy for oligoprogressive metastatic breast cancer: a retrospective cohort study.
Combining surgery to destroy remaining tumors with ongoing drug therapy helps manage advanced breast cancer in selected patients, though more evidence is needed.
A retrospective Dutch cancer center cohort study demonstrates the feasibility of combining local ablative treatment with systemic therapy continuation for oligoprogressive metastatic breast cancer. The clinical outcomes data support this as a practiced strategy in selected patients, though randomized prospective evidence is needed to establish efficacy and patient selection criteria.
What the study was
- Study design
- retrospective cohort study
- Population
- Oligoprogressive metastatic breast cancer patients (Dutch cancer center)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer treatment and research communications
Why it surfaced
Addresses emerging oligoprogression clinical strategy in metastatic breast cancer; captured via sentinel scan; retrospective design and modest scope limit to STANDARD priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.